Richard Hoffmann1,2,3, Callum Logan4, Michael O'Callaghan4,5, Kirsten Gormly6, Ken Chan6, Darren Foreman4,7. 1. Department of Urology, Lyell McEwin Hospital, Elizabeth Vale, Adelaide, SA, 5112, Australia. rjwhoffmann@gmail.com. 2. Department of Urology, Repatriation General Hospital, Adelaide, Australia. rjwhoffmann@gmail.com. 3. Discipline of Surgery, University of Adelaide, Adelaide, Australia. rjwhoffmann@gmail.com. 4. Department of Urology, Repatriation General Hospital, Adelaide, Australia. 5. South Australian Prostate Cancer Clinical Outcome Collaborative, Adelaide, Australia. 6. Dr Jones and Partners Medical Imaging, Adelaide, Australia. 7. Discipline of Surgery, University of Adelaide, Adelaide, Australia.
Abstract
INTRODUCTION: Multiparametric MRI (mpMRI) is useful in detecting anterior prostate tumours. Due to the location of anterior tumours, they are often diagnosed with a large size and may be suspicious for extra-prostatic extension (EPE). We aim to evaluate whether PI-RADS v2 is more accurate in assessing anterior prostate lesions identified on mpMRI compared to PI-RADS v1. METHODS: Patients with anterior prostate lesions diagnosed on mpMRI who proceeded to a cognitive fusion transperineal prostate biopsy were identified. Each mpMRI was blinded and read by two experienced prostate MRI radiologists and assigned a PI-RADS v1 and PI-RADS v2 score, and the presence of EPE was estimated. Correlation was made with transperineal histopathology and, where relevant, radical prostatectomy histopathology. Concordance measures between PI-RADS v1 and PI-RADS v2, and between examiners of the same PI-RADS score were calculated using a weighted kappa. RESULTS: Fifty-eight consecutive men were identified. Concordance between the examiners for PI-RADS v1 and for v2 showed substantial agreement (version 1: weighted kappa 0.71; version 2: weighted kappa 0.69). There was no difference in accuracy when using PI-RADS v1 or PI-RADS v2 to predict clinically significant cancer. There was poor correlation between EPE measured on mpMRI compared with EPE in radical prostatectomy histopathology. CONCLUSION: PI-RADS v2 is reproducible between radiologists but does not have improved accuracy for diagnosing anterior tumours of the prostate when compared to PI-RADS v1. Multiparametric MRI is accurate at detecting anterior tumours with a sensitivity of 86-88%.
INTRODUCTION: Multiparametric MRI (mpMRI) is useful in detecting anterior prostate tumours. Due to the location of anterior tumours, they are often diagnosed with a large size and may be suspicious for extra-prostatic extension (EPE). We aim to evaluate whether PI-RADS v2 is more accurate in assessing anterior prostate lesions identified on mpMRI compared to PI-RADS v1. METHODS:Patients with anterior prostate lesions diagnosed on mpMRI who proceeded to a cognitive fusion transperineal prostate biopsy were identified. Each mpMRI was blinded and read by two experienced prostate MRI radiologists and assigned a PI-RADS v1 and PI-RADS v2 score, and the presence of EPE was estimated. Correlation was made with transperineal histopathology and, where relevant, radical prostatectomy histopathology. Concordance measures between PI-RADS v1 and PI-RADS v2, and between examiners of the same PI-RADS score were calculated using a weighted kappa. RESULTS: Fifty-eight consecutive men were identified. Concordance between the examiners for PI-RADS v1 and for v2 showed substantial agreement (version 1: weighted kappa 0.71; version 2: weighted kappa 0.69). There was no difference in accuracy when using PI-RADS v1 or PI-RADS v2 to predict clinically significant cancer. There was poor correlation between EPE measured on mpMRI compared with EPE in radical prostatectomy histopathology. CONCLUSION: PI-RADS v2 is reproducible between radiologists but does not have improved accuracy for diagnosing anterior tumours of the prostate when compared to PI-RADS v1. Multiparametric MRI is accurate at detecting anterior tumours with a sensitivity of 86-88%.
Entities:
Keywords:
Anterior tumours; MRI; Multiparametric; PI-RADS; Prostate cancer
Authors: Christopher Lim; Trevor A Flood; Shaheed W Hakim; Wael M Shabana; Jeffrey S Quon; Mohamed El-Khodary; Rebecca E Thornhill; Soufiane El Hallani; Nicola Schieda Journal: J Magn Reson Imaging Date: 2015-08-25 Impact factor: 4.813
Authors: L Schimmöller; M Quentin; C Arsov; R S Lanzman; A Hiester; R Rabenalt; G Antoch; P Albers; D Blondin Journal: Eur Radiol Date: 2013-06-12 Impact factor: 5.315
Authors: Dmitry Volkin; Baris Turkbey; Anthony N Hoang; Soroush Rais-Bahrami; Nitin Yerram; Annerleim Walton-Diaz; Jeffrey W Nix; Bradford J Wood; Peter L Choyke; Peter A Pinto Journal: BJU Int Date: 2014-10-18 Impact factor: 5.588
Authors: Satheesh Krishna; Christopher S Lim; Matthew D F McInnes; Trevor A Flood; Wael M Shabana; Robert S Lim; Nicola Schieda Journal: J Magn Reson Imaging Date: 2017-04-07 Impact factor: 4.813
Authors: Caroline M A Hoeks; Martijn G Schouten; Joyce G R Bomers; Stefan P Hoogendoorn; Christina A Hulsbergen-van de Kaa; Thomas Hambrock; Henk Vergunst; J P Michiel Sedelaar; Jurgen J Fütterer; Jelle O Barentsz Journal: Eur Urol Date: 2012-02-01 Impact factor: 20.096
Authors: Nathan Lawrentschuk; Masoom A Haider; Nikhil Daljeet; Andrew Evans; Ants Toi; Antonio Finelli; John Trachtenberg; Alexandre Zlotta; Neil Fleshner Journal: BJU Int Date: 2009-10-08 Impact factor: 5.588
Authors: Amr Mahran; Kirtishri Mishra; Laura Bukavina; Fredrick Schumacher; Anna Quian; Christina Buzzy; Carvell T Nguyen; Vikas Gulani; Lee E Ponsky Journal: Int Urol Nephrol Date: 2019-05-02 Impact factor: 2.370
Authors: Armando Stabile; Francesco Giganti; Veeru Kasivisvanathan; Gianluca Giannarini; Caroline M Moore; Anwar R Padhani; Valeria Panebianco; Andrew B Rosenkrantz; Georg Salomon; Baris Turkbey; Geert Villeirs; Jelle O Barentsz Journal: Eur Urol Oncol Date: 2020-03-17
Authors: Sonia Gaur; Nathan Lay; Stephanie A Harmon; Sreya Doddakashi; Sherif Mehralivand; Burak Argun; Tristan Barrett; Sandra Bednarova; Rossanno Girometti; Ercan Karaarslan; Ali Riza Kural; Aytekin Oto; Andrei S Purysko; Tatjana Antic; Cristina Magi-Galluzzi; Yesim Saglican; Stefano Sioletic; Anne Y Warren; Leonardo Bittencourt; Jurgen J Fütterer; Rajan T Gupta; Ismail Kabakus; Yan Mee Law; Daniel J Margolis; Haytham Shebel; Antonio C Westphalen; Bradford J Wood; Peter A Pinto; Joanna H Shih; Peter L Choyke; Ronald M Summers; Baris Turkbey Journal: Oncotarget Date: 2018-09-18